Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies

European Journal of Cancer

Volumn 75, Issue , 2017, Pages 169-178

  Choong, Ee Siang ^a   Lo, Serigne ^b   Drummond, Martin ^b   Fogarty, Gerald B ^b,d,e   Menzies, Alexander M ^b,e,f   Guminski, Alexander ^b,e,f   Shivalingam, Brindha ^b,c,e   Clarke, Kathryn ^d   Long, Georgina V ^b,e,f   Hong, Angela M ^b,d,e  

^a Chris O Brien Lifehouse   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^d Genesis Cancer Care Pty Ltd   (Australia)

^e Mater Hospital   (Australia)

^f ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

Anti PD 1 antibody; BRAF inhibitors; Brain metastasis; Immunotherapy; Melanoma; Stereotactic radiosurgery; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE INHIBITOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; B RAF KINASE; BRAF PROTEIN, HUMAN; MAP2K1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METASTATIC MELANOMA; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; SYSTEMIC THERAPY; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; BRAIN NEOPLASMS; IMMUNOTHERAPY; MELANOMA; MOLECULARLY TARGETED THERAPY; MORTALITY; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOSURGERY; SECONDARY; SKIN TUMOR; TREATMENT OUTCOME; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; MALE; MAP KINASE KINASE 1; MELANOMA; MIDDLE AGED; MOLECULAR TARGETED THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTO-ONCOGENE PROTEINS B-RAF; RADIOSURGERY; SKIN NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85013477431     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.01.007     Document Type: Article

References (36)

1. [1] Fife, K.M., Colman, M.H., Stevens, G.N., Firth, I.C., Moon, D., Shannon, K.F., et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:7 (2004), 1293–1300.
2. [2] Staudt, M., Lasithiotakis, K., Leiter, U., Meier, F., Eigentler, T., Bamberg, M., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:8 (2010), 1213–1218.
3. [3] Liew, D.N., Kano, H., Kondziolka, D., Mathieu, D., Niranjan, A., Flickinger, J.C., et al. Outcome predictors of Gamma knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 114:3 (2011), 769–779.
4. [4] Neal, M.T., Chan, M.D., Lucas, J.T. Jr., Loganathan, A., Dillingham, C., Pan, E., et al. Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases. World Neurosurg 82:6 (2014), 1250–1255.
5. [5] Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:26 (2011), 2507–2516.
6. [6] Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (London, England) 380:9839 (2012), 358–365.
7. [7] Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
8. [8] Larkin, J., Ascierto, P.A., Dreno, B., Atkinson, V., Liszkay, G., Maio, M., et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371:20 (2014), 1867–1876.
9. [9] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:1 (2015), 23–34.
10. [10] Long, G.V., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England) 386:9992 (2015), 444–451.
11. [11] Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:1 (2015), 30–39.
12. [12] Robert, C., Long, G.V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:4 (2015), 320–330.
13. [13] Robert, C., Schachter, J., Long, G.V., Arance, A., Grob, J.J., Mortier, L., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:26 (2015), 2521–2532.
14. [14] Knisely, J.P., Yu, J.B., Flanigan, J., Sznol, M., Kluger, H.M., Chiang, V.L., Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:2 (2012), 227–233.
15. [15] Margolin, K., Ernstoff, M.S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:5 (2012), 459–465.
16. [16] Silk, A.W., Bassetti, M.F., West, B.T., Tsien, C.I., Lao, C.D., Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:6 (2013), 899–906.
17. [17] Tazi, K., Hathaway, A., Chiuzan, C., Shirai, K., Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4:1 (2015), 1–6.
18. [18] Queirolo, P., Spagnolo, F., Ascierto, P.A., Simeone, E., Marchetti, P., Scoppola, A., et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 118:1 (2014), 109–116.
19. [19] Goldberg, S.B., Gettinger, S.N., Mahajan, A., Chiang, A.C., Herbst, R.S., Sznol, M., et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol 17:7 (2016), 976–983.
20. [20] Dummer, R., Goldinger, S.M., Turtschi, C.P., Eggmann, N.B., Michielin, O., Mitchell, L., et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. Eur J Cancer 50:3 (2014), 611–621.
21. [21] Long, G.V., Trefzer, U., Davies, M.A., Kefford, R.F., Ascierto, P.A., Chapman, P.B., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:11 (2012), 1087–1095.
22. [22] Harding, J.J., Catalanotti, F., Munhoz, R.R., Cheng, D.T., Yaqubie, A., Kelly, N., et al. A retrospective evaluation of vemurafenib as treatment for BRAF-mutant melanoma brain metastases. Oncologist 20:7 (2015), 789–797.
23. [23] Ramanujam, S., Schadendorf, D., Long, G.V., Systemic therapies for melanoma brain metastases: which drug for whom and when?. Chin Clin Oncol, 4(2), 2015, 25.
24. [24] Sperduto, P.W., Berkey, B., Gaspar, L.E., Mehta, M., Curran, W., A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 70:2 (2008), 510–514.
25. [25] Sperduto, P.W., Chao, S.T., Sneed, P.K., Luo, X., Suh, J., Roberge, D., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 77:3 (2010), 655–661.
26. [26] Kiess, A.P., Wolchok, J.D., Barker, C.A., Postow, M.A., Tabar, V., Huse, J.T., et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:2 (2015), 368–375.
27. [27] Ahmed, K.A., Stallworth, D.G., Kim, Y., Johnstone, P.A., Harrison, L.B., Caudell, J.J., et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Annals of oncology. official J Eur Soc Med Oncology/ESMO 27:3 (2016), 434–441.
28. [28] Dzienis, M.R., Atkinson, V.G., Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review. Melanoma Res 24:4 (2014), 349–353.
29. [29] Ahmed, K.A., Freilich, J.M., Sloot, S., Figura, N., Gibney, G.T., Weber, J.S., et al. LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases. J Neurooncol 122:1 (2015), 121–126.
30. [30] Ly, D., Bagshaw, H.P., Anker, C.J., Tward, J.D., Grossmann, K.F., Jensen, R.L., et al. Local control after stereotactic radiosurgery for brain metastases in patients with melanoma with and without BRAF mutation and treatment. J Neurosurg 123:2 (2015), 395–401.
31. [31] Wolf, A., Zia, S., Verma, R., Pavlick, A., Wilson, M., Golfinos, J.G., et al. Impact on overall survival of the combination of BRAF inhibitors and stereotactic radiosurgery in patients with melanoma brain metastases. J Neurooncol 127:3 (2016), 607–615.
32. [32] Gallaher, I.S., Watanabe, Y., DeFor, T.E., Dusenbery, K.E., Lee, C.K., Hunt, M.A., et al. BRAF mutation is associated with improved local control of melanoma brain metastases treated with gamma knife radiosurgery. Front Oncol, 6, 2016.
33. [33] Fogarty, G., Morton, R.L., Vardy, J., Nowak, A.K., Mandel, C., Forder, P.M., et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients–a randomised phase III trial. BMC Cancer, 11, 2011, 142.
34. [34] Mathew, M., Tam, M., Ott, P.A., Pavlick, A.C., Rush, S.C., Donahue, B.R., et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23:3 (2013), 191–195.
35. [35] Du Four, S., Hong, A., Chan, M., Charakidis, M., Duerinck, J., Wilgenhof, S., et al. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med, 2014, 2014, 417913.
36. [36] Patel, B.G., Ahmed, K.A., Johnstone, P.A., Yu, H.H., Etame, A.B., Initial experience with combined BRAF and MEK inhibition with stereotactic radiosurgery for BRAF mutant melanoma brain metastases. Melanoma Res 26:4 (2016), 382–386.